›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:TruSight Tumor 15 Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
IlluminaType:
Laboratory Developed Test
Related tests:
TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
Cancer:
Solid Tumor
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), FOXL2 (Forkhead Box L2), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), FOXL2 (Forkhead Box L2), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), HER-2 (Human epidermal growth factor receptor 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), RET (Ret Proto-Oncogene), TP53 (Tumor protein P53)
Method:
Next generation sequencing (NGS)